Reasons to Retain Baxter International Stock in Your Portfolio Now
AI Sentiment
Neutral
5/10
as of 12-26-2025 3:43pm EST
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CONSHOHOCKEN |
| Market Cap: | 57.4B | IPO Year: | N/A |
| Target Price: | $354.85 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.96 | EPS Growth: | 5.71 |
| 52 Week Low/High: | $223.92 - $377.54 | Next Earning Date: | 02-04-2026 |
| Revenue: | $321,332,819,000 | Revenue Growth: | 9.31% |
| Revenue Growth (this year): | 7.2% | Revenue Growth (next year): | 6.62% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Executive Vice President
Avg Cost/Share
$342.10
Shares
3,351
Total Value
$1,146,377.10
Owned After
23,891.141
SEC Form 4
Executive Vice President
Avg Cost/Share
$345.00
Shares
1,677
Total Value
$578,565.00
Owned After
18,796.464
SEC Form 4
President & CEO
Avg Cost/Share
$343.45
Shares
5,096
Total Value
$1,750,221.20
Owned After
68,059
SEC Form 4
SVP & Chief Accounting Officer
Avg Cost/Share
$343.24
Shares
4,031
Total Value
$1,383,580.29
Owned After
17,154
SEC Form 4
President & CEO
Avg Cost/Share
$366.64
Shares
5,096
Total Value
$1,868,397.44
Owned After
68,059
SEC Form 4
President & CEO
Avg Cost/Share
$326.80
Shares
5,097
Total Value
$1,665,699.60
Owned After
68,059
SEC Form 4
Executive Vice President
Avg Cost/Share
$313.28
Shares
1,886
Total Value
$590,846.08
Owned After
23,891.141
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Elizabeth S | COR | Executive Vice President | Dec 19, 2025 | Sell | $342.10 | 3,351 | $1,146,377.10 | 23,891.141 | |
| Battaglia Silvana | COR | Executive Vice President | Dec 19, 2025 | Sell | $345.00 | 1,677 | $578,565.00 | 18,796.464 | |
| Mauch Robert P. | COR | President & CEO | Dec 18, 2025 | Sell | $343.45 | 5,096 | $1,750,221.20 | 68,059 | |
| Krikorian Lazarus | COR | SVP & Chief Accounting Officer | Dec 17, 2025 | Sell | $343.24 | 4,031 | $1,383,580.29 | 17,154 | |
| Mauch Robert P. | COR | President & CEO | Nov 18, 2025 | Sell | $366.64 | 5,096 | $1,868,397.44 | 68,059 | |
| Mauch Robert P. | COR | President & CEO | Oct 20, 2025 | Sell | $326.80 | 5,097 | $1,665,699.60 | 68,059 | |
| Campbell Elizabeth S | COR | Executive Vice President | Oct 1, 2025 | Sell | $313.28 | 1,886 | $590,846.08 | 23,891.141 |
COR Breaking Stock News: Dive into COR Ticker-Specific Updates for Smart Investing
AI Sentiment
Neutral
5/10
AI Sentiment
Neutral
4/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Neutral
4/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
8/10
See how COR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "COR Cencora Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.